Last reviewed · How we verify
isoniazid and rifapentine
isoniazid and rifapentine is a Antitubercular agent Small molecule drug developed by National Taiwan University Hospital. It is currently in Phase 3 development for Pulmonary tuberculosis, Meningeal tuberculosis. Also known as: INH/RPT, 1H3P3, PRIFTIN, RPT.
Isoniazid and rifapentine work by inhibiting the synthesis of mycolic acid in Mycobacterium tuberculosis, ultimately leading to the death of the bacteria.
Isoniazid and rifapentine work by inhibiting the synthesis of mycolic acid in Mycobacterium tuberculosis, ultimately leading to the death of the bacteria. Used for Pulmonary tuberculosis, Meningeal tuberculosis.
At a glance
| Generic name | isoniazid and rifapentine |
|---|---|
| Also known as | INH/RPT, 1H3P3, PRIFTIN, RPT, P |
| Sponsor | National Taiwan University Hospital |
| Drug class | Antitubercular agent |
| Target | InhA (enoyl-acyl carrier protein reductase), RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
Isoniazid is a prodrug that is activated by the enzyme catalase-peroxidase in M. tuberculosis. It then inhibits the enzyme enoyl-acyl carrier protein reductase (InhA), which is essential for the synthesis of mycolic acid. Rifapentine, on the other hand, is a rifamycin antibiotic that inhibits DNA-dependent RNA polymerase, which is necessary for the transcription of M. tuberculosis genes.
Approved indications
- Pulmonary tuberculosis
- Meningeal tuberculosis
Common side effects
- Hepatotoxicity
- Neuropathy
- Gastrointestinal disturbances
Key clinical trials
- Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB (PHASE2, PHASE3)
- Asymptomatic TB With Innovative Modified Short-course Regimens (PHASE4)
- Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women (PHASE1)
- Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings (NA)
- A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV (PHASE1, PHASE2)
- One-month Latent Tuberculosis Treatment for Renal Transplant Candidates (PHASE4)
- ThiPhiSA: New Pathways to Prevention From Community TB Screening in South Africa (NA)
- Window Prophylaxis for Pediatric Tuberculosis Prevention Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- isoniazid and rifapentine CI brief — competitive landscape report
- isoniazid and rifapentine updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI
Frequently asked questions about isoniazid and rifapentine
What is isoniazid and rifapentine?
How does isoniazid and rifapentine work?
What is isoniazid and rifapentine used for?
Who makes isoniazid and rifapentine?
Is isoniazid and rifapentine also known as anything else?
What drug class is isoniazid and rifapentine in?
What development phase is isoniazid and rifapentine in?
What are the side effects of isoniazid and rifapentine?
What does isoniazid and rifapentine target?
Related
- Drug class: All Antitubercular agent drugs
- Target: All drugs targeting InhA (enoyl-acyl carrier protein reductase), RNA polymerase
- Manufacturer: National Taiwan University Hospital — full pipeline
- Therapeutic area: All drugs in Infectious disease
- Indication: Drugs for Pulmonary tuberculosis
- Indication: Drugs for Meningeal tuberculosis
- Also known as: INH/RPT, 1H3P3, PRIFTIN, RPT, P
- Compare: isoniazid and rifapentine vs similar drugs
- Pricing: isoniazid and rifapentine cost, discount & access